title: 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.
abstract: Overexpression of the HER2/neu protooncogene has been shown to correlate with poor clinical prognosis. A murine monoclonal antibody (4D5) directed against the extracellular domain (ECD) of p185HER2 has been shown to inhibit in vitro and in vivo growth of carcinomas overexpressing HER2 and has been humanized (rhuMAb HER2). The objective of the study was the identification of an agent which might be useful for in vitro studies, tumor imaging and/or radioimmunotherapy by linking beta-emitting radionuclides to these HER2-targeted antibodies. Murine 4D5 and humanized rhuMAb HER2 were radiolabeled with 125I, 131I or 186Re. Physical characteristics (TCA precipitability, SDS-PAGE, size exclusion chromatography), binding affinities to the HER2 ECD (in an ELISA and on SK-BR-3 cells) and antiproliferative activities of the radiolabeled antibodies were determined. Although 131I-4D5 and 131I-rhuMAb HER2 usually retained > 85% ECD binding, they exhibited increased aggregation and fragment content, drastically reduced antiproliferative activities and poor stability upon storage at 4 degrees C. For these antibody preparations, conservation of binding did not necessarily correlate with preservation of bioactivity indicating the importance of bioactivity determinations in radiolabeled antibody studies. Conversely, 4D5 and rhuMAb HER2 labeled with 125I or 186Re maintained physical properties, ECD binding, antiproliferative activities and were stable upon storage at 4 degrees C for at least 8 days. The superior retention of physical and biological characteristics of 186Re-labeled 4D5 and rhuMAb HER2 compared with their 131I-labeled counterparts suggests the potential for their use as radioimaging and radioimmunotherapeutic agents in the treatment of HER2 overexpressing tumors.
authors.affiliation: Department of BioAnalytical Technology, Genentech Inc., So. San Francisco, CA 94080, USA.
authors.forename: C E
authors.initials: CE
authors.lastname: Kotts
authors.forename: F M
authors.initials: FM
authors.lastname: Su
authors.forename: C
authors.initials: C
authors.lastname: Leddy
authors.forename: T
authors.initials: T
authors.lastname: Dodd
authors.forename: S
authors.initials: S
authors.lastname: Scates
authors.forename: M R
authors.initials: MR
authors.lastname: Shalaby
authors.forename: C M
authors.initials: CM
authors.lastname: Wirth
authors.forename: D
authors.initials: D
authors.lastname: Giltinan
authors.forename: R W
authors.initials: RW
authors.lastname: Schroff
authors.forename: A R
authors.initials: AR
authors.lastname: Fritzberg
authors.forename: H M
authors.initials: HM
authors.lastname: Shepard
authors.forename: D J
authors.initials: DJ
authors.lastname: Slamon
authors.forename: B M
authors.initials: BM
authors.lastname: Hutchins
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007553:Isotope Labeling; D051379:Mice; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D012211:Rhenium / Q000627:therapeutic use*; D020298:U937 Cells
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases; D012211:Rhenium